Hi Jim,
Arcadium Lithium (LTM) is the result of the $9.7bn all-scrip merger between Allkem and Livent, it trades in the US under the ticker code of (ALTM US), while being list on the ASX as a CDI. The logic between the tie-up was sound, as it produced a vertically integrated business with multiple product lines across the world but its still going to struggle as we’ve witnessed when the lithium price heads south in an aggressive manner.
- So far in 2024 LTM down -30% is compared to PLS which is up +6.6%.
We prefer PLS believing it will continue to perform strongly relative to its peers and the market hence we are long in the MM Active Growth Portfolio. Conversely, LTM still needs to work through the integration of the two respective businesses which will take time to produce results and carries with it risks which may easily take 1-2 years before it convinces investors. Essentially, PLS is just a cleaner, less complicated play on the same theme.